Physician profile
Heather E Boscia
NPI 1487967386
$2,671.16
in general payments reported to CMS, 2019-2025
31 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,180 · 2022: $410 · 2023: $510 · 2024: $429 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,081.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $457.27 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $314.51 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $310.98 | 2021-2024 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $305.78 | 2021-2024 | Mounjaro, Jardiance |
| Pfizer INC. | $160.19 | 2021-2024 | |
| Incyte Corporation | $125.00 | 2025 | Zynyz |
| Abbott Laboratories | $107.39 | 2021-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $101.02 | 2021-2024 | Rexulti |
| Amarin Pharma, INC. | $70.98 | 2021 | |
| Exact Sciences Corporation | $68.65 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $65.76 | 2021-2024 | Shingrix, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $52.57 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.03 | 2021 | |
| Merck Sharp & Dohme LLC | $49.39 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.13 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $44.97 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $43.05 | 2021 | |
| Amgen INC. | $42.12 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.02 | 2021-2024 | Jardiance, Tradjenta |
| Ironwood Pharmaceuticals, INC | $28.83 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.62 | 2024 | |
| Esperion Therapeutics, INC. | $20.15 | 2021 | |
| Exeltis, USA INC. | $19.11 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.07 | 2021 | |
| Exelixis INC. | $18.21 | 2025 | Cabometyx |
| Lundbeck LLC | $18.03 | 2024 | Rexulti |
| Eisai INC. | $16.71 | 2021 | |
| Almatica Pharma LLC | $16.08 | 2021 | |
| Mylan Specialty L.P. | $15.08 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.60 | 2023 | Xifaxan, Trulance |
| Masimo Corporation | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Boscia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.